Point72 Hong Kong Ltd Acquires Shares of 15,438 LivaNova PLC (NASDAQ:LIVN)

Point72 Hong Kong Ltd acquired a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,438 shares of the company's stock, valued at approximately $715,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in LIVN. KBC Group NV raised its stake in shares of LivaNova by 130.5% in the 4th quarter. KBC Group NV now owns 99,928 shares of the company's stock valued at $4,628,000 after purchasing an additional 56,580 shares during the period. Rhumbline Advisers grew its holdings in shares of LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after buying an additional 899 shares in the last quarter. Principal Financial Group Inc. raised its position in LivaNova by 2.6% in the 4th quarter. Principal Financial Group Inc. now owns 175,878 shares of the company's stock valued at $8,145,000 after buying an additional 4,476 shares during the last quarter. Paradice Investment Management LLC lifted its stake in LivaNova by 15.3% in the 4th quarter. Paradice Investment Management LLC now owns 486,821 shares of the company's stock valued at $22,545,000 after acquiring an additional 64,680 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its position in LivaNova by 122.8% during the 4th quarter. New York State Common Retirement Fund now owns 37,557 shares of the company's stock worth $1,739,000 after acquiring an additional 20,699 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Robert W. Baird lifted their price objective on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Needham & Company LLC reiterated a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research note on Tuesday, May 13th. Mizuho decreased their target price on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. StockNews.com downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. Finally, Stifel Nicolaus cut their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, LivaNova currently has a consensus rating of "Buy" and a consensus target price of $59.29.

LivaNova Stock Performance

LivaNova stock traded down $1.28 during mid-day trading on Wednesday, hitting $43.60. 138,440 shares of the company's stock traded hands, compared to its average volume of 645,553. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The firm has a 50 day simple moving average of $38.61 and a two-hundred day simple moving average of $44.76. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $61.94. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of 104.23 and a beta of 0.84.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.